Cargando…
Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy
BACKGROUND: Cardiomyocyte hypertrophy is a hallmark of cardiac dysfunction in patients with aortic stenosis (AS), and can be triggered by left ventricular (LV) pressure overload in mice by aortic banding (AB). Syndecan-4 is a transmembrane heparan sulphate proteoglycan which is found increased in th...
Autores principales: | Lunde, Ida G., Aronsen, J. Magnus, Melleby, A. Olav, Strand, Mari E., Skogestad, Jonas, Bendiksen, Bård A., Ahmed, M. Shakil, Sjaastad, Ivar, Attramadal, Håvard, Carlson, Cathrine R., Christensen, Geir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712407/ https://www.ncbi.nlm.nih.gov/pubmed/36205855 http://dx.doi.org/10.1007/s11033-022-07985-y |
Ejemplares similares
-
Syndecan-4 Is Essential for Development of Concentric Myocardial Hypertrophy via Stretch-Induced Activation of the Calcineurin-NFAT Pathway
por: Finsen, Alexandra V., et al.
Publicado: (2011) -
Syndecan‐4 Protects the Heart From the Profibrotic Effects of Thrombin‐Cleaved Osteopontin
por: Herum, Kate M., et al.
Publicado: (2020) -
The female syndecan-4(−/−) heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels
por: Støle, Thea Parsberg, et al.
Publicado: (2022) -
Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy
por: Bernt, Alexander, et al.
Publicado: (2016) -
Syndecan-4(–/–) Mice Have Smaller Muscle Fibers, Increased Akt/mTOR/S6K1 and Notch/HES-1 Pathways, and Alterations in Extracellular Matrix Components
por: Rønning, Sissel Beate, et al.
Publicado: (2020)